Cellceutix Phase 2 Brilacidin Trial Progresses to Highest Dose Cohort for the Induction of Remission of Mild-to-Moderate Ulcerative Colitis
February 22, 2017 12:43 ET
|
Cellceutix Corporation
BEVERLY, Mass., Feb. 22, 2017 (GLOBE NEWSWIRE) -- Cellceutix Corporation, (OTCQB:CTIX) (“the Company”), a clinical stage biopharmaceutical company developing innovative therapies with dermatology,...
Cellceutix Reports on Q2 Fiscal 2017, Prepares for Important Clinical Milestones
February 16, 2017 07:30 ET
|
Cellceutix Corporation
BEVERLY, Mass., Feb. 16, 2017 (GLOBE NEWSWIRE) -- Cellceutix Corporation, (OTCQB:CTIX) (“the Company”), a clinical stage biopharmaceutical company developing innovative therapies with dermatology,...
Cellceutix Announces Initiation of Main Clinical Site for Phase 2a Trial of p53 Drug Candidate Kevetrin in the Treatment of Platinum-Resistant/Refractory Ovarian Cancer
February 10, 2017 08:00 ET
|
Cellceutix Corporation
BEVERLY, Mass., Feb. 10, 2017 (GLOBE NEWSWIRE) -- Cellceutix Corporation, (OTCQB:CTIX) (“the Company”), a clinical stage biopharmaceutical company developing innovative therapies with dermatology,...
Cellceutix’s Brilacidin Demonstrates Promise in Treating Ulcerative Colitis Supported by Endoscopic Assessment, Patient-Reported Outcomes
January 23, 2017 07:00 ET
|
Cellceutix Corporation
BEVERLY, Mass., Jan. 23, 2017 (GLOBE NEWSWIRE) -- Cellceutix Corporation, (OTCQB:CTIX) (“the Company”), a clinical stage biopharmaceutical company developing innovative therapies with dermatology,...
Cellceutix Strongly Denounces Criminal Enterprise Mako Research, Who Published “Fake News” Full of Lies and Innuendo
January 17, 2017 14:46 ET
|
Cellceutix Corporation
BEVERLY, Mass., Jan. 17, 2017 (GLOBE NEWSWIRE) -- Cellceutix Corporation, (OTCQB:CTIX) (“the Company”), a clinical stage biopharmaceutical company developing innovative therapies with dermatology,...
Cellceutix Completes Enrollment in Second of Three Planned Cohorts in Phase 2 Clinical Trial of Brilacidin for Inflammatory Bowel Disease
January 17, 2017 10:00 ET
|
Cellceutix Corporation
BEVERLY, Mass., Jan. 17, 2017 (GLOBE NEWSWIRE) -- Cellceutix Corporation, (OTCQB:CTIX) (“the Company”), a clinical stage biopharmaceutical company developing innovative therapies with dermatology,...
Cellceutix to Present at Biotech Showcase 2017; Brilacidin for Oral Mucositis Nears Interim Results
January 04, 2017 08:15 ET
|
Cellceutix Corporation
BEVERLY, Mass., Jan. 04, 2017 (GLOBE NEWSWIRE) -- Cellceutix Corporation, (OTCQB:CTIX) (“the Company”), a clinical stage biopharmaceutical company developing innovative therapies with dermatology,...
Cellceutix Wishes Shareholders Happy Holidays, Prepares for 2017 Focused on Partnerships
December 22, 2016 10:00 ET
|
Cellceutix Corporation
BEVERLY, Mass., Dec. 22, 2016 (GLOBE NEWSWIRE) -- Cellceutix Corporation, (OTCQB:CTIX) (“the Company”), a clinical stage biopharmaceutical company developing innovative therapies with dermatology,...
Cellceutix Reports 24 Core Phase 2b Clinical Trial Sites for Oral Prurisol Treatment of Moderate-To-Severe Psoriasis Initiated and Open for Screening
December 19, 2016 07:30 ET
|
Cellceutix Corporation
BEVERLY, Mass., Dec. 19, 2016 (GLOBE NEWSWIRE) -- Cellceutix Corporation (OTCQB:CTIX) (“the Company”), a clinical stage biopharmaceutical company developing innovative therapies with dermatology,...
Cellceutix Reports Advances in Developing Kevetrin as an Oral Ovarian Cancer Treatment; Company Seeks to Develop World’s First p53-Modulating Oral Cancer Drug
December 15, 2016 07:30 ET
|
Cellceutix Corporation
BEVERLY, Mass., Dec. 15, 2016 (GLOBE NEWSWIRE) -- Cellceutix Corporation, (OTCQB:CTIX) (“the Company”), a clinical stage biopharmaceutical company developing innovative therapies with dermatology,...